相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Diagnosis and management of Duchenne muscular dystrophy, part 3: primary care, emergency management, psychosocial care, and transitions of care across the lifespan
David J. Birnkrant et al.
LANCET NEUROLOGY (2018)
Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management (vol 17, pg 251, 2018)
J. F. Zimmermann et al.
LANCET NEUROLOGY (2018)
Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management
David J. Birnkrant et al.
LANCET NEUROLOGY (2018)
Deflazacort versus prednisone/prednisolone for maintaining motor function and delaying loss of ambulation: A post HOC analysis from the ACT DMD trial
Perry B. Shieh et al.
MUSCLE & NERVE (2018)
Eteplirsen treatment for Duchenne muscular dystrophy Exon skipping and dystrophin production
Jay S. Charleston et al.
NEUROLOGY (2018)
A randomized placebo-controlled phase 3 trial of an antisense oligonucleotide, drisapersen, in Duchenne muscular dystrophy
Nathalie Goemans et al.
NEUROMUSCULAR DISORDERS (2018)
Exosome-Mediated Benefits of Cell Therapy in Mouse and Human Models of Duchenne Muscular Dystrophy
Mark A. Aminzadeh et al.
STEM CELL REPORTS (2018)
Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management
David J. Birnkrant et al.
LANCET NEUROLOGY (2018)
A Novel NF-κB Inhibitor, Edasalonexent (CAT-1004), in Development as a Disease-Modifying Treatment for Patients With Duchenne Muscular Dystrophy: Phase 1 Safety, Pharmacokinetics, and Pharmacodynamics in Adult Subjects
Joanne M. Donovan et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Craig M. McDonald et al.
LANCET (2017)
Stunning pharmacological properties of DS-5141b, an antisense oligonucleotide consisting of 2′-O,4′-C-ethylene-bridged nucleic acids and 2′-O-methyl RNA, on dystrophin mRNA exon skipping
K. Takaishi et al.
NEUROMUSCULAR DISORDERS (2017)
Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy
Jerry R. Mendell et al.
ANNALS OF NEUROLOGY (2016)
Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophy
Robert C. Griggs et al.
NEUROLOGY (2016)
Modifier genes and their effect on Duchenne muscular dystrophy
Andy H. Vo et al.
CURRENT OPINION IN NEUROLOGY (2015)
The TREAT-NMD DMD Global Database: Analysis of More than 7,000 Duchenne Muscular Dystrophy Mutations
Catherine L. Bladen et al.
HUMAN MUTATION (2015)
Efficacy of idebenone on respiratory function in patients with Duchenne muscular dystrophy not using glucocorticoids (DELOS): a double-blind randomised placebo-controlled phase 3 trial
Gunnar M. Buyse et al.
LANCET (2015)
Border between natural product and drug: Comparison of the related benzoquinones idebenone and coenzyme Q(10)
Nuni Gueyen et al.
REDOX BIOLOGY (2015)
VBP15, a novel anti-inflammatory and membrane-stabilizer, improves muscular dystrophy without side effects
Christopher R. Heier et al.
EMBO MOLECULAR MEDICINE (2013)
Newborn bloodspot screening for Duchenne Muscular Dystrophy: 21 years experience in Wales (UK)
Stuart J. Moat et al.
EUROPEAN JOURNAL OF HUMAN GENETICS (2013)
Glucocorticoid Treatment for the Prevention of Scoliosis in Children with Duchenne Muscular Dystrophy: Long-Term Follow-up
David E. Lebel et al.
JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME (2013)
Corticosteroids in Duchenne muscular dystrophy: Major variations in practice
Robert C. Griggs et al.
MUSCLE & NERVE (2013)
The cooperative international neuromuscular research group Duchenne natural history study: Glucocorticoid treatment preserves clinically meaningful functional milestones and reduces rate of disease progression as measured by manual muscle testing and other commonly used clinical trial outcome measures
Erik K. Henricson et al.
MUSCLE & NERVE (2013)
Evidence-Based Path to Newborn Screening for Duchenne Muscular Dystrophy
Jerry R. Mendell et al.
ANNALS OF NEUROLOGY (2012)
Overexpression of Galgt2 in skeletal muscle prevents injury resulting from eccentric contractions in both mdx and wild-type mice
Paul T. Martin et al.
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY (2009)
Theoretic Applicability of Antisense-Mediated Exon Skipping for Duchenne Muscular Dystrophy Mutations
Annemieke Aartsma-Rus et al.
HUMAN MUTATION (2009)
PTC124 targets genetic disorders caused by nonsense mutations
Ellen M. Welch et al.
NATURE (2007)
Functional and morphological recovery of dystrophic muscles in mice treated with deacetylase inhibitors
G. C. Minetti et al.
NATURE MEDICINE (2006)
Entries in the Leiden Duchenne muscular dystrophy mutation database: An overview of mutation types and paradoxical cases that confirm the reading-frame rule
Annemieke Aartsma-Rus et al.
MUSCLE & NERVE (2006)
Therapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patients
A Aartsma-Rus et al.
HUMAN MOLECULAR GENETICS (2003)
Loss of myostatin attenuates severity of muscular dystrophy in mdx mice
KR Wagner et al.
ANNALS OF NEUROLOGY (2002)
Overexpression of the cytotoxic T cell GalNAc transferase in skeletal muscle inhibits muscular dystrophy in mdx mice
HH Nguyen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Modular flexibility of dystrophin: Implications for gene therapy of Duchenne muscular dystrophy
SQ Harper et al.
NATURE MEDICINE (2002)
分享论文
